Actelion drug setback unlikely to derail J&J talks: analysts
ZURICH (Reuters) - A blow to Actelion's Opsumit drug in a test is unlikely to have an impact on talks over a strategic deal with Johnson & Johnson , analysts said on Monday, as the Swiss drugmaker's... [Source]
Publication Date:Origin: reuters.com
Category: innovationNews
Topics: Johnson, analysts, talks, unlikely, drugmaker's, Swiss, strategic, impact, Opsumit, Actelion's, (Reuters), ZURICH, derail, setback, Actelion
Source: http://feeds.reuters.com/~r/news/deals/~3/oJSUFwu_Lfc/us-actelion-opsumit-study-idUSKBN1570KW